A retrospective study found that a radiomic-clinicopathologic nomogram performed better than other tools in predicting biochemical recurrence-free survival after surgery for prostate cancer.
A new study of men with recurrent prostate cancer following radiation therapy shows that biopsy findings and MRI can reliably identify index lesions for possible salvage partial gland ablation.
The overall and failure-free survival benefit of adding prostate radiation therapy to standard of care for metastatic prostate cancer declines with increasing number of bone metastases, a study found.
Biparametric magnetic resonance imaging may offer advantages over PSA testing and ultrasonography by detecting more clinically significant prostate cancers without increasing the number of men advised to undergo prostate biopsies or overdiagnosed with clinically insignificant cancers.
In an online survey, 17.2% of patients with genitourinary cancers reported they delayed or avoided seeking medical care because of the COVID-19 pandemic.
Real-world data show that a combination of a first-generation anti-androgen drug and androgen deprivation therapy is no better than ADT alone in improving outcomes among men with metastatic castration-sensitive prostate cancer.
Study reveals patients’ and survivors’ perception of discussions with their healthcare team regarding options, costs, and impact on work related to prostate cancer treatment.
A cancer center in New York City safely managed patients with localized prostate cancer during the height of the COVID-19 pandemic in 2020, providing insights for handling a second COVID-19 wave.
Investigators say they believe their study is the first to show a link between circulating tumor cell counts and progression-free and overall survival in men with metastatic hormone-sensitive prostate cancer.
Investigators studied whether sexual orientation affects screening for prevalent gender-specific cancers including prostate, breast, and cervical cancer.
Kessel et al present the final efficacy and safety results from a phase 2 study of radium-223 plus enzalutamide vs enzalutamide monotherapy in metastatic castration-resistant prostate cancer (mCRPC).
Sensitivity analyses were performed to assess the effect of placebo to darolutamide crossover on overall survival benefit among ARAMIS trial participants.
Retrospective study of more than 32,000 veterans sought to determine the incidence, management, and mortality of men with prostate cancer who experience depression.
Data analysis evaluated the associations between rates of treatment noncompletion and radiotherapy fractionation schedules for men with localized prostate cancer.
